By Colin Kellaher
Gilead Sciences Inc. (GILD) and Novo Nordisk A/S (NOVO-B.KO, NVO) on Friday said they will collaborate on a clinical trial combining compounds from their pipelines in nonalcoholic steatohepatitis, a chronic liver condition commonly known as NASH.
The companies said the trial will be a proof-of-concept study combining Novo's semaglutide and Gilead's cilofexor and firsocostat for the treatment of patients with NASH.
Gilead, a Foster City, Calif., biopharmaceutical company, and Danish pharmaceutical company Novo said they also may collaborate on preclinical research to advance understanding of the disease, which often affects people with diabetes and metabolic syndrome.
Write to Colin Kellaher at firstname.lastname@example.org